Tuesday, October 19, 2021
HomeNews ReleaseUFS: Department of Nuclear Medicine treats first patient with advanced prostate cancer

UFS: Department of Nuclear Medicine treats first patient with advanced prostate cancer

The University of the Free State (UFS) Department of Nuclear Medicine has, for the first time, started using Lutetium 177 PSMA (Lu-177 PSMA) therapy for the treatment of metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer.

The UFS and the Free State province are now joining other South African universities, such as the University of Pretoria the University of the Witwatersrand, and other provinces in using this method to treat MCRPC patients.

Dr Osayande Evbuomwan, a senior lecturer and medical specialist in the Department of Nuclear Medicine,  Faculty of Health Sciences, says they started treating their first MCRP patient (first cycle) with peptide receptor radionuclide therapy (PRRT) in July. It is the first time that Lutetium 177 PSMA – a type of PRRT used for treating patients with MCRPC – has been used in the Free State. This method is used on MCRPC patients who are not eligible for chemotherapy or have failed first- or second-line chemotherapy. Expertise and funds are now available for this treatment

Evbuomwan was trained and exposed to this therapy at the University of the Witwatersrand during his registrar training in nuclear medicine. When he joined the UFS in 2019, he – with the always available help of the Head of Department Dr Gerrit Engelbrecht – pushed for the therapy to be used in the department.

“We are happy that expertise is now available and that some funds have been released for this treatment to commence," he said. "The index patient is very sick with MCRPC and was too ill to qualify for first-line chemotherapy. Each patient will need about four-six cycles for complete treatment. The patient is being treated in the Department of Nuclear Medicine at the Universitas Academic Hospital and Annex.”

“We hope he will be able to complete at least four cycles and respond well to the treatment. We believe that the ability to administer this treatment now is good news for the Free State, as people in this province also deserve to be exposed to this level of treatment. We are hoping the government will continue to provide more funds for more of these patients to be treated in our facility."

It was budgeted to treat five patients (20 cycles), with each cycle (just the Lu-177 PSMA) costing more than R50 000.

Prostate cancer is one of the leading causes of morbidity and mortality in the world, including South Africa, added Evbuomwan. When it progresses to the very advanced stage of MCRPC, the prognosis becomes very bad.

Various conventional systemic therapies, including first- and second-line chemotherapy, can be used to treat patients at this stage. However, not all patients are fit for chemotherapy. The few who are fit usually end up failing the first-line chemotherapy, which has a lot of undesirable side effects and requires long-stay hospital admissions.

Only a few centres are able to offer second-line chemotherapy, so many of these patients end up suffering from prolonged pain before eventually dying from the disease.

PRRT is a targeted nuclear medicine therapy delivering very high levels of radiation specifically to cancer cells, because these cells express specific receptors to which certain peptides can bind. This specificity to cancer cells offers the advantage of providing lower doses of radiation and damage to normal organs and tissues, a characteristic that conventional therapies do not offer, added Evbuomwan.

Lutetium 177 PSMA (Lu-177 PSMA) is a type of PRRT used for treating patients with MCRPC, who are not eligible for chemotherapy or have failed first-line chemotherapy. Numerous research studies around the world have proven that this treatment improves quality of life, slows down disease progression, and improves overall survival, with little or very tolerable side effects in most patients.

The University of Pretoria is one of the pioneers of this treatment in the world, having done a lot of research with it since 2017. Other provinces like the Western Cape and KwaZulu-Natal have also recently become involved with the therapy, which is expensive and requires a lot of expertise. It also involves the input of a multidisciplinary team (MDT), which must at least include a nuclear medicine physician, a radiation oncologist, and a urologist. The Departments of Urology and Radiation Oncology at the UFS were also instrumental in the initiation of the therapy and form part of the MDT team at the UFS in the management of these patients.

Treatment puts department, university, and hospital on the map

Evbuomwan says the ability to administer this treatment puts the department, the UFS, and the hospital on the map, alongside other top universities within and outside the country. “It also creates an avenue for us to gather data for research purposes and for publications. We are now able to offer a promising, safe, and highly efficacious therapy for patients with MCRPC in the Free State. Some of these patients no longer need to travel to other provinces to get the treatment.”

There are plans to expand the treatment to more patients – and hospital management, who were present at the first treatment, are excited and looking forward to the outcome of this current treatment.

Issued by the University of the Free State

 

Subscribe to our Newsletter

Receive Medical Brief's free weekly e-newsletter.

* indicates required